BIT Capital’s X4 Pharmaceuticals XFOR Stock Holding History

BIT Capital’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,500	Closed	-$77K	–	182
2022 Q3	$77K	Buy	+1,500	New	+$51.8K	0.01%	132

Other funds holding XFOR

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BIT Capital's XFOR Position: Q4 2022 in Review

BIT Capital sold out of X4 Pharmaceuticals (XFOR) in Q4 2022, closing a stake of 1,500 shares — an estimated $77K sold.

BIT Capital first reported a position in XFOR in Q3 2022 and held it in 1 quarter. The position peaked at $77K in Q3 2022. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2022.

BIT Capital reported no remaining X4 Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
BIT Capital sold 1,500 X4 Pharmaceuticals shares in Q4 2022, an estimated $77K.
BIT Capital first reported a position in X4 Pharmaceuticals in Q3 2022 and held it in 1 quarter.
BIT Capital's X4 Pharmaceuticals position peaked at $77K in Q3 2022.
52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2022.

Based on BIT Capital's 13F filing for Q4 2022, filed 12 Feb 2025.